Kite Pharma is looking stronger than ever in the race to get a CAR-T product onto the market following positive topline results from a primary six-month analysis for KTE-C19 in aggressive NHL (ZUMA-1).
Data from the pivotal Phase I/II ZUMA-1 trial of Kite Pharma Inc.'s CAR-T cell therapy KTE-C19 in patients with aggressive non-Hodgkin’s Lymphoma will support a rolling BLA submission due shortly and a regulatory filing in Europe later this year.
The latest data showed that responses achieved in patients treated with KTE-C19 at the three-month mark remained durable at six...
First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.
Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.
In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.
UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.
Private Company Edition: Antares’ lead asset will enter the clinic in 2026 after Lilly committed up to $2.5bn for Scorpion’s Phase I/II PI3Kα inhibitor STX-478. Also, Amplify raised $200m for its first biotech VC fund and Mosanna raised an $80m series A round, among other financings.
